4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:分子类,蛋白类,抗体类,生化类试剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > Selleck Chemicals/Fedratinib(TG101348)/S2736
商品详细Selleck Chemicals/Fedratinib(TG101348)/S2736
Selleck Chemicals/Fedratinib(TG101348)/S2736
Selleck Chemicals/Fedratinib(TG101348)/S2736
商品编号: S2736
品牌: Selleck Chemicals
市场价: ¥11400.00
美元价: 6840.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
DescriptionFedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Fedratinib also inhibits FMS-like tyrosine kinase 3 (FLT3) and RET (c-RET) with IC50 of 15 nM and 48 nM, respectively. Fedratinib has potential antineoplastic activity. Fedratinib inhibits proliferation and induces apoptosis. Phase 2.
Targets
JAK2 [1](Cell-free assay)JAK2 (V617F) [1](Cell-free assay)FLT3 [1](Cell-free assay)RET [1](Cell-free assay)
3 nM3 nM15 nM48 nM
In vitro

TG-101348 also significantly inhibits JAK2 V617F, Flt3, and Ret with IC50 of 3 nM, 15 nM, and 48 nM, respectively. TG101348 has an IC50 ~300-fold higher for the closely related JAK3 and is a less potent inhibitor of the JAK1 and TYK2 family members. TG101348 inhibits proliferation of a human erythroblast leukemia (HEL) cell line that harbors the JAK2V617F mutation, as well as a murine pro-B cell line expressing human JAK2V617F (Ba/F3 JAK2V617F), with IC50 of 305 nM and 270 nM, respectively. TG-101348 also inhibits proliferation of parental Ba/F3 cells to a comparable level, with IC50 of ~420 nM. TG101348 treatment reduces STAT5 phosphorylation at concentrations that parallel the concentrations required to inhibit cell proliferation. TG101348 induces apoptosis in both HEL and Ba/F3 JAK2V617F cells in a dose-dependent manner. TG101348 does not show proapoptotic activity in control normal human dermal fibroblasts at concentrations up to 10 μM, and the antiproliferative IC50 against fibroblasts is >5 μM. [1] TG101348 treatment decreases GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F+ progenitor differentiation, and inhibits STAT5 as well as GATA S310 phosphorylation. [2] TG101348 inhibits the proliferation of HMC-1.1 (KITV560G) cells, with somewhat lower potency than HMC-1.2 (KITD816V, KITV560G) cells, with IC50 of 740 nM and 407 nM, respectively. [3]

Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
H1975MnzkRZBweHSxc3nzJGF{e2G7MniyNE42NTJizszNNVq1S44yOTJvNEigbC=>MWrEUXNQMYfpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVzNIraPFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NUi2PVIyOCd-MkW4OlkzOTB:L3G+
H1650M4TR[GFxd3C2b4Ppd{BCe3OjeR?=NYPIbXdHOC53LUKg{txOMnqzNVIuPDhiaB?=MWDEUXNQMULpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVzNWTPXY9sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlkzOTBpPkK1PFY6OjFyPD;hQi=>
H1975MWDGeY5kfGmxbjDBd5NigQ>?NVHLenI4OC5{NT2xJO69VQ>?NFr4XVAzPCCqM1jxRmROW09?M2rWTYlvcGmkaYTzJIV5eHKnc4Ppc44hd2ZiYYDvdJRwe2m|LYLlcIF1WRicILveIVqdiCEY3ytXGwtKEKlbD2yMEB{fXK4aYpckwhYEmDUB?=MUe8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4OUKxNEc,OjV6NkmyNVA9N2F-
H1650NITONnZHfW6ldHnvckBCe3OjeR?=MUGwMlI2NTFizszNNEfTR20zPCCqMUXEUXNQMVTpcohq[mm2czDlfJBzXO|aX;uJI9nKGGyb4D0c5Nqey2{ZXzheIVlKHC{b4TlbY4hSmOuLWjMMEBD[2xvMjygd5Vzfmm4aX6sJHhKSVB?M4LOVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ3OE[5NlExLz5{NUi2PVIyODxxYU6=
H1975M{TNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXuxJO69VQ>?NYHUPJlTPDhiaB?=MoHkSG1UVw>?NUjSTXZse2Wwc3n0bZpmeyClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjbZR6KG:oIHXycI91cW6rYh?=MVe8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4OUKxNEc,OjV6NkmyNVA9N2F-
H1650NYSxVHM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrXVpo4OSEQvF2=MmnHOFghcA>?NXT1fW45TE2VTx?=Mn7Bd4Vve2m2aYrld{BkWyuczD0c{B1cGViY4n0c5RwgGmlaYT5JI9nKGW{bH;0bY5q[g>?NYPES5hrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlkzOTBpPkK1PFY6OjFyPD;hQi=>
CD4+TMmC5SpVv[3Srb36gRZN{[Xl?MXqwMlAyNTFizszNMoLpOFghcA>?MnTUSG1UVw>?NET4UFFzWS3Y3XzJJRpSCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJI9nKEqDS{KgZY5lKFOWQWSzxsA>Moj4QIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3N{K1N|UoRjJ3NUeyOVM2RC:jPh?=
Caco-2NVnrPYxUTnWwY4Tpc44hSXO|YYm=M4fvbFAuOTJyIN88US=>NWrP[5lLPyCvaX6=MUDpcohq[mm2czD0bIlidWmwZTD1dJRic2Vid3n0bEBidiCLQ{WwxsBwiB{LkJCpOK2VQ>?M23bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ3ME[zOlczLz5{NUC2N|Y4OjxxYU6=
Caco-2M2HWT2Z2dmO2aX;uJGF{e2G7Ml73NVAwPTBxMUCwJO69VQ>?NVPGUXV[OiCqMmjM[IVkemWjc3XzJJRpSCobIX4JI9nKFt|SG30bIlidWmwZTDhZ5Jwe3NidHjlJI1wdm:uYYnldkB4cXSqIFnDOVAhd2ZiNj61xsDPxE1?MkDRQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkO2O|IoRjJ3ME[zOlczRC:jPh?=
HEK293 MSRNILrTVJHfW6ldHnvckBCe3OjeR?=NV;GeVdEOC1zMDFOwG0>MYW3JI1qdg>?NWnp[GRrcW6qaXLpeJMhcFSKVGKyJJdqfGhiYX6gTWM2OMLib3[gNU4zyqEEtV2=MUS8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4M{[3Nkc,OjVyNkO2O|I9N2F-
MedB-1MowSpVv[3Srb36gRZN{[Xl?NHn6NG8yNzJizszNM4m0NlI1KGh?NV7OdWV3GWlcnXhd4V{KFOWQWS2JJBpd3OyaH;yfYxifGmxbjDjc45kW62cnH0bY9vKGSncHXu[IVvfGy7MV28ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl5N{[2PEc,OjR7N{e2Olg9N2F-
U2940NULDT3g4TnWwY4Tpc44hSXO|YYm=MVGxM|Ih|ryPNFLDb40zPCCqMmPX[IVkemWjc3XzJHNVSVR4IIDoc5NxcG:{eXzheIlwdiClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6Mn7rQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{e2OlgoRjJ2OUe3OlY5RC:jPh?=
K1106M162TmZ2dmO2aX;uJGF{e2G7M2DsblEwOiEQvF2=M3G0R|I1KGh?MX7k[YNzWG|ZYOgV3RCXDZicHjvd5Bpd3K7bHH0bY9vKGOxbnPlcpRz[XSrb36g[IVxW6mZX70cJk>MnnRQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{e2OlgoRjJ2OUe3OlY5RC:jPh?=
K562NFr0U5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfoNE0yKM7:TR?=MY[3NkBpMVnpcohq[mm2czDLOVYzKGOnbHygdJJwdGmoZYLheIlwdiCjdDDobYdpKGOxbnPlcpRz[XSrb36=NY[2bWZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3O|U{ODhpPkK0O|c2OzB6PD;hQi=>
MDA-MB-468NXywSndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXOzJOK2VQ>?MX60PEBpM3T0OYVvcGGwY3XkJJNq[mOuNjDpcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJnDqA>?MXm8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ4MkixPEc,OjR4NkK4NVg9N2F-
MDA-MB-468MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIruZZExNTRizszNMWq0PEBpM4 OZJme3WudIOgd4lodmmoaXPhcpQhdG:|czDv[kB3cWGkaXzpeJkh[2:vcHHy[YQhfG9iUlmtRnBKKGGub37lM1roflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2Nk[yPFE5Lz5{NE[2NlgyQDxxYU6=
L428NH[zRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY[wMVUh|ryPNEnTbHE1QCCqNYXST4xUcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=>M3fCelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
KMH2MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWCwMVUh|ryPMXq0PEBpMWXpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaXpZ4FvfGy7MX:8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzMEiyO{c,OjR4MUC4Nlc9N2F-
L1236Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEf3d40xNTVizszNNH2xeYY1QCCqNHvaXW9qdmirYnn0d{BkWyuIHfyc5d1cCC|aXfubYZq[2GwdHz5NETrSmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
SUPHD1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDhNE02KM7:TR?=NGIdos1QCCqNVSwVpJUcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=>NVPJfWNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVA5OjdpPkK0OlExQDJ5PD;hQi=>
HDLM2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXYNE02KM7:TR?=M4D1[FQ5KGh?MVzpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaXpZ4FvfGy7NH3xeYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
K1106PNF7n[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUSwMVUh|ryPNGH2N2c1QCCqM2rE[IlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm=Mn QIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUC4NlcoRjJ2NkGwPFI4RC:jPh?=
L428MYXBdI9xfG:|aYOgRZN{[Xl?NXH5cGZbOC9yLk[yOU8yNjJ3IN88US=>NIPMeY81QCCqMVpcoR2[2W|IITo[UBieG:ydH;zbZPDqA>?NYezNXVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVA5OjdpPkK0OlExQDJ5PD;hQi=>
KMH2NUHTe3l7SXCxcITvd4l{KEG|c3H5M1r3TlAwOC54MkWvNU4zPSEQvF2=MmnQOFghcA>?Ml3PbY5lfWOnczD0bIUh[XCxcITvd4l{yqB?M4nFN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
L1236NXzIfGJJSXCxcITvd4l{KEG|c3H5NEXNc|kxNzBwNkK1M|EvOjVizszNMkKwOFghcA>?M1;DVIlvHWlZYOgeIhmKGGyb4D0c5Nqe8LiNHSwVZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
SUPHD1NFfYW4RCeG:ydH;zbZMhSXO|YYm=MV[wM|AvPjJ3L{GuNlUh|ryPNVnYSW5ZPDhiaB?=Mn7PbY5lfWOnczD0bIUh[XCxcITvd4l{yqB?M333SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
HDLM2Mkf3RZBweHSxc3nzJGF{e2G7MlzvNE8xNjZ{NT:xMlI2KM7:TR?=NHjzNWc1QCCqMnnPbY5lfWOnczD0bIUh[XCxcITvd4l{yqB?M1jnXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
K1106PMoKwRZBweHSxc3nzJGF{e2G7MWmwM|AvPjJ3L{GuNlUh|ryPM2HDZ|Q5KGh?NWX5[YhIcW6mdXPld{B1cGViYYDvdJRwe2m|wrC=M1qxS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
L428MXfGeY5kfGmxbjDBd5NigQ>?MWGwMVUh|ryPMXWyOEBpMULpcohq[mm2czDKRWszN1OWQWSgd4lodmGuaX7nNGT2bHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
KMH2M2TGbGZ2dmO2aX;uJGF{e2G7MmfHNE02KM7:TR?=Moq1NlQhcA>?MnHRbY5pcWKrdIOgTmFMOi:VVFHUJJNq26jbHnu[y=>MYq8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzMEiyO{c,OjR4MUC4Nlc9N2F-
L1236NWTBU|BMTnWwY4Tpc44hSXO|YYm=M3qZVAuPSEQvF2=MViyOEBpMVTpcohq[mm2czDKRWszN1OWQWSgd4lodmGuaX7nM2PtUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ2NkGwPFI4Lz5{NE[xNFgzPzxxYU6=
SUPHD1MVGeY5kfGmxbjDBd5NigQ>?M2m5PVAuPSEQvF2=NGrxVYozPCCqNUfrVlR6cW6qaXLpeJMhUkGNMj;TWGFVKHOrZ37hcIlvw>?NVPxdFJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVA5OjdpPkK0OlExQDJ5PD;hQi=>
HDLM2NXjB[IZVTnWwY4Tpc44hSXO|YYm=NUHKPGNQOC13IN88US=>NInafmUzPCCqNVu5eJR1cW6qaXLpeJMhUkGNMj;TWGFVKHOrZ37hcIlvw>?NF21UGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NE[xNFgzPyd-MkS2NVA5Ojd:L3G+
K1106PMnrJSpVv[3Srb36gRZN{[Xl?M2fZdFAuPSEQvF2=NHvqfHMzPCCqNUjYcYx1cW6qaXLpeJMhUkGNMj;TWGFVKHOrZ37hcIlvw>?MoHpQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUC4NlcoRjJ2NkGwPFI4RC:jPh?=
MM.1SMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLibohrUUN3ME2xMVMh|ryPNEPTOWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NEW4OFExOSd-MkS1PFQyODF:L3G+
TpoR JAK2 WTMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVG0b4tQUUN3ME2xMlQhMDFwM,MAl|EvPSlizszNNVLyRmtHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVE4QTBpPkK0NlUyPzlyPD;hQi=>
TpoR JAK2 V617FMl:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFWzfoFKSzVyPUCuPEApOC554pETNE46MSEQvF2=NWCbWFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVE4QTBpPkK0NlUyPzlyPD;hQi=>
TpoR W515LNVXmN|BTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mln0TWM2OD1yLkigLFAvP+LCk{GuNEkh|ryPMVy8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3MUe5NEc,OjR{NUG3PVA9N2F-
Bcr-ablNEPtdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorNTWM2OD1{LkegLFIvOuLCk{OuN{kh|ryPNYDUTJFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOVE4QTBpPkK0NlUyPzlyPD;hQi=>
JAK2 TWNWPFfVZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MliyTWM2OD1zLkigLFEvPeLCk{KuN{kh|ryPNGHu[Yg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{NEK1NVc6OCd-MkSyOVE4QTB:L3G+
JAK2 V617FMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTBwNjCoNE436oDVMD63LUDPxE1?MWq8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ3MUe5NEc,OjR{NUG3PVA9N2F-
MedB-1NUjlS4xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3P5Z|Qh|ryPM33POVI1NzR6L{eyJIg>NIPc|NFVVORMXrpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVvGWwdHz5M1fXV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ|OEWyN|Y3Lz5{M{i1NlM3PjxxYU6=
K1106NILEVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUe0JO69VQ>?MWCyOE81QC95MjDoNYeyV2JvTE2VTx?=NYrMOFFCcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBlXCnbnTlcpRtgQ>?MX28ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3MkO2Okc,OjN6NUKzOlY9N2F-
U2940MoxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXW0JO69VQ>?MkXGNlQwPDhxN{KgbC=>NWT5WGk5TE2VTx?=MUDpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVvGWwdHz5NIHHTG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{M{i1NlM3Pid-MkO4OVI{PjZ:L3G+
FE-PDMmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HJdlAvODZ|LUSg{txOM3;4OmlEPTB;OT61JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHig[I9{SCmZYDlcoRmdnSueR?=NGnxe4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{M{O3NlY3QSd-MkOzO|I3Pjl:L3G+
HELMkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPjNE4xPjNvNDFOwG0>NXm0TWtwUUN3ME2xMlUh|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVvGWwdHz5MWS8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5Mk[2PUc,OjN|N{K2Olk9N2F-
K-562NXHOcWlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrvcXp7OC5yNkOtOEDPxE1?M2HidGlEPTB;Mj61JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHig[I9{SCmZYDlcoRmdnSueR?=NXW1cnZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|I3PjlpPkKzN|czPjZ7PD;hQi=>
L-82 M3znfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vYZlAvODZ|LUSg{txOM4Ha[GlEPTB;MD65PEDPxE1uIHnubIljcXS|IHPlcIwh3Kxd4ToJIRwe2ViZHXw[Y5lW62bIm=MVi8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5Mk[2PUc,OjN|N{K2Olk9N2F-
MAC-1MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nFOlAvODZ|LUSg{txOMYrJR|UxRTBwNUKg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7NWPEVW9qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|I3PjlpPkKzN|czPjZ7PD;hQi=>
MAC-2AM330VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mom3NE4xPjNvNDFOwG0>NGHJeolKSzVyPUCuOlkh|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVvGWwdHz5Mn3KQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|N{K2OlkoRjJ|M{eyOlY6RC:jPh?=
MAC-2BNITWTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PZZlAvODZ|LUSg{txOMXjJR|UxRTBwNUSg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7M1zqT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ|M{eyOlY6Lz5{M{O3NlY3QTxxYU6=
MY-LAM{fnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zhS|AvODZ|LUSg{txOM2XGR2lEPTB;Mj6xJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHig[I9{SCmZYDlcoRmdnSueR?=MmHzQIEhfGG{Z3X0QUdg[myjbnunJIhzWZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|N{K2OlkoRjJ|M{eyOlY6RC:jPh?=
NC-NCMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HTR|AvODZ|LUSg{txOMYjJR|UxRTFwMDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHTvd4UhGWyZX7k[Y51dHl?NFvJc4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{M{O3NlY3QSd-MkOzO|I3Pjl:L3G+
SE-AXMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4Pke|AvODZ|LUSg{txOMmPsTWM2OD1zLkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7NYjLVllmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO|I3PjlpPkKzN|czPjZ7PD;hQi=>
SR-786NIf6cYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fO[VAvODZ|LUSg{txONIjicpBKSzVyPUSuOkDPxE1uIHnubIljcXS|IHPlcIwh3Kxd4ToJIRwe2ViZHXw[Y5lW62bIm=MVi8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5Mk[2PUc,OjN|N{K2Olk9N2F-
M-MOKM1yyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7YT2UzPSEEtV5CpC=>MoTnNlQwPDhxN{KgbC=>NELweJNFVVORNYPJepk4cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBlXCnbnTlcpRtgQ>?NVjBR21zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OVMyPTdpPkKxPFU{OTV5PD;hQi=>
HELNX3ad3VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;Bd2x5UUN3ME2zNFUhdk1?MW[8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN7NEW1OEc,OTh|OUS1OVQ9N2F-
Ba/F3 JAK2V617FM2fmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTJ5MDDuUS=>M13BZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzF6M{m0OVU1Lz5zOEO5OFU2PDxxYU6=
MV4-11MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?MlnEO|IhcHK|M1rvXWFvfGmycn;sbYZmemG2aYlJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtfGm2ZYKtZox2SCjc4PhfUwhTUN3MDC9JFAvODd7IN88UU4>NICxTW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJuWRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
MM1SNV;4cFZZSW62aYDyc4xqmW{YYTpeoUh[XO|YYm=NULKRXVrPzJiaILzM{TzbmFvfGmycn;sbYZmemG2aYlJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV2xV{BkWyuczDh[pRmeiB5MjDodpMh[nlidIL5dIFvKGKudXWg[ZhkdHW|aX;uJIF{e2G7LDDJR|UxKD1iMTFOwG0vMXq8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
NB1643NXvWNIVneUiWUzDhd5NigQ>?MlP2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5IhHK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{BkWyucx?=M3TJTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1mC6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MCNGmXXRyUFSVIHHzd4F6NIPFXnByUFSVIH;mJJBmGmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBtSCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>MVO8ZUB1[XKpZYS9K39jdGGwazegbJJmj1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data

Assay
MethodsTest IndexPMID
Western blot
p-JAK2 / p-STAT1 / p-STAT3 / p-STAT6 / p-STAT5 / JAK2 ;

PubMed: 24610827

Western analysis of pJAK2 and the downstream pSTATs following treatment with vehicle or the indicated concentrations of fedratinib for 24 hours. Total JAK2 and GAPDH are similarly analyzed.

c-Myc / PIM1 ;

PubMed: 24610827

Western analysis of c-MYC and PIM1 protein levels in cHL and MLBCL cell lines treated with vehicle or fedratinib at the indicated concentration for 24 hours. Data are representative of three independent experiments.

24610827
Growth inhibition assay
Cell proliferation ;

PubMed: 24610827

Cellular proliferation of cHL cell lines (L428, KMH2, L1236, SUPHD1 and HDLM2) and the MLBCL cell line (K1106P), following treatment with vehicle or fedratinib at indicated concentration for 48 hours. For each cell line, the previously reported 9p24.1/JAK2 copy numbers (7) are indicated in parenthesis. At a given dose of the JAK2 inhibitor (1.25 μM), a Kruskal-Wallis test was performed to assess the association between the ranked values of inhibition and copy number gain (p = .009, cHL and MLBCL cell lines; p = .019, cHL cell lines).

24610827
In vivo

TG101348 has potential for efficacious treatment of JAK2V617F-associated myeloproliferative diseases (MPD). In treated animals, there is a statistically significant reduction in hematocrit and leukocyte count, a dose-dependent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis, correlated with surrogate endpoints, including reduction/elimination of JAK2V617F disease burden, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction. There are no apparent toxicities and no effect on T cell number. [1] Oral administration of TG101348 (120 mg/kg) significantly inhibits PV progenitor erythroid differentiation in vivo. [2]

品牌介绍
Selleck Chemicals是世界领先的高性能的生命科学产品供应商之一,主要致力于提供MAPK和PI3K/Akt/mTOR等上百个信号通路的高特异性小分子抑制剂。Selleck 产品线补充非常及时,可以提供行业内最新的抑制剂类产品。同时Selleck也是专业的高通量筛选抑制剂分子库、API、天然产物和多肽供应商。